QNRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quoin Pharmaceuticals Ltd (QNRX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's focus on developing a first-in-class treatment for Netherton Syndrome, its recent Orphan Drug Designation in Japan, and its multiple global partnerships present strong growth potential. While technical indicators are mixed, the long-term prospects and analyst ratings support a buy decision.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 50.162, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 4.227, and resistance is at 5.029. The technicals suggest no strong short-term signals but do not negate the long-term potential.
QRX003 received Orphan Drug Designation in Japan, aiding commercialization. Quoin has established a subsidiary in Japan and formed nine commercial partnerships across 61 countries. Analysts view the company as a high-conviction opportunity with significant upside potential.
Moving averages are bearish, and there is no recent insider or hedge fund activity indicating strong confidence.
No financial data available for assessment.
Analysts have consistently rated the stock as a Buy, with price targets ranging from $12 to $35. The consensus is that the company's lead asset, QRX003, has significant potential as a differentiated therapy for Netherton Syndrome, a condition with no approved treatments.
